KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

被引：22
作者：
Zhang, Zining [1 ,2 ]
Zhang, Heng [1 ,2 ]
Liao, Xiang [1 ,2 ]
Tsai, Hsiang-i [1 ,2 ]
机构：
[1] Jiangsu Univ, Inst Med Imaging & Artificial Intelligence, Zhenjiang, Peoples R China
[2] Jiangsu Univ, Affiliated Hosp, Dept Med Imaging, Zhenjiang, Peoples R China
来源：
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2023年 / 11卷
基金：
中国国家自然科学基金;
关键词：
PDAC; KRAS mutation; phosphokinase; metabolic reprogramming; therapy resistance; poorer prognosis; MUTANT KRAS; GLUTAMINE-METABOLISM; MOUSE MODEL; CANCER; CELL; INHIBITOR; INITIATION; GLYCOLYSIS; KRAS(G12D); EFFICACY;
D O I：
10.3389/fcell.2023.1147676
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It has a poor response to conventional therapy and has an extremely poor 5-year survival rate. PDAC is driven by multiple oncogene mutations, with the highest mutation frequency being observed in KRAS. The KRAS protein, which binds to GTP, has phosphokinase activity, which further activates downstream effectors. KRAS mutation contributes to cancer cell proliferation, metabolic reprogramming, immune escape, and therapy resistance in PDAC, acting as a critical driver of the disease. Thus, KRAS mutation is positively associated with poorer prognosis in pancreatic cancer patients. This review focus on the KRAS mutation patterns in PDAC, and further emphases its role in signal transduction, metabolic reprogramming, therapy resistance and prognosis, hoping to provide KRAS target therapy strategies for PDAC.
引用
收藏
页数：16
相关论文
共 160 条
  • [1] Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
    Abdel-Wahab, Ali F.
    Mahmoud, Waheed
    Al-Harizy, Randa M.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 150
  • [2] Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
    Aguirre, AJ
    Bardeesy, N
    Sinha, M
    Lopez, L
    Tuveson, DA
    Horner, J
    Redston, MS
    DePinho, RA
    [J]. GENES & DEVELOPMENT, 2003, 17 (24) : 3112 - 3126
  • [3] High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
    Allenson, K.
    Castillo, J.
    San Lucas, F. A.
    Scelo, G.
    Kim, D. U.
    Bernard, V.
    Davis, G.
    Kumar, T.
    Katz, M.
    Overman, M. J.
    Foretova, L.
    Fabianova, E.
    Holcatova, I.
    Janout, V.
    Meric-Bernstam, F.
    Gascoyne, P.
    Wistuba, I.
    Varadhachary, G.
    Brennan, P.
    Hanash, S.
    Li, D.
    Maitra, A.
    Alvarez, H.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (04) : 741 - 747
  • [4] A gene-environment-induced epigenetic program initiates tumorigenesis
    Alonso-Curbelo, Direna
    Ho, Yu-Jui
    Burdziak, Cassandra
    Maag, Jesper L. V.
    Morris, John P.
    Chandwani, Rohit
    Chen, Hsuan-An
    Tsanov, Kaloyan M.
    Barriga, Francisco M.
    Luan, Wei
    Tasdemir, Nilgun
    Livshits, Geulah
    Azizi, Elham
    Chun, Jaeyoung
    Wilkinson, John E.
    Mazutis, Linas
    Leach, Steven D.
    Koche, Richard
    Pe'er, Dana
    Lowe, Scott W.
    [J]. NATURE, 2021, 590 (7847) : 642 - 648
  • [5] Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer
    Andersen, Dana K.
    Korc, Murray
    Petersen, Gloria M.
    Eibl, Guido
    Li, Donghui
    Rickels, Michael R.
    Chari, Suresh T.
    Abbruzzese, James L.
    [J]. DIABETES, 2017, 66 (05) : 1103 - 1110
  • [6] Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer
    Azizi, Nawab
    Toma, Jelena
    Martin, Mickenzie
    Khalid, Muhammad Faran
    Mousavi, Fatemeh
    Win, Phyo Wei
    Borrello, Maria Teresa
    Steele, Nina
    Shi, Jiaqi
    di Magliano, Marina Pasca
    Pin, Christopher L.
    [J]. ONCOGENE, 2021, 40 (17) : 3118 - 3135
  • [7] Targeting KRAS in pancreatic cancer: new drugs on the horizon
    Bannoura, Sahar F.
    Uddin, Md. Hafiz
    Nagasaka, Misako
    Fazili, Farzeen
    Al-Hallak, Mohammed Najeeb
    Philip, Philip A.
    El-Rayes, Bassel
    Azmi, Asfar S.
    [J]. CANCER AND METASTASIS REVIEWS, 2021, 40 (03) : 819 - 835
  • [8] Challenges and Opportunities for Pancreatic Cancer Immunotherapy
    Bear, Adham S.
    Vonderheide, Robert H.
    O'Hara, Mark H.
    [J]. CANCER CELL, 2020, 38 (06) : 788 - 802
  • [9] Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
    Bond, Michael J.
    Chu, Ling
    Nalawansha, Dhanusha A.
    Li, Ke
    Crews, Craig M.
    [J]. ACS CENTRAL SCIENCE, 2020, 6 (08) : 1367 - 1375
  • [10] Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism
    Bott, Alex J.
    Shen, Jianliang
    Tonelli, Claudia
    Zhan, Le
    Sivaram, Nithya
    Jiang, Ya-Ping
    Yu, Xufen
    Bhatt, Vrushank
    Chiles, Eric
    Zhong, Hua
    Maimouni, Sara
    Dai, Weiwei
    Velasquez, Stephani
    Pan, Ji-An
    Muthalagu, Nathiya
    Morton, Jennifer
    Anthony, Tracy G.
    Feng, Hui
    Lamers, Wouter H.
    Murphy, Daniel J.
    Guo, Jessie Yanxiang
    Jin, Jian
    Crawford, Howard C.
    Zhang, Lanjing
    White, Eileen
    Lin, Richard Z.
    Su, Xiaoyang
    Tuveson, David A.
    Zong, Wei-Xing
    [J]. CELL REPORTS, 2019, 29 (05): : 1287 - +
12345678910